GENFIT Announces Mid-Year Liquidity Figures
Company Announcements

GENFIT Announces Mid-Year Liquidity Figures

Genfit SA (GNFT) has released an update.

GENFIT SA, a biopharmaceutical company focusing on liver diseases, has reported its half-year liquidity contract figures with Crédit Industriel et Commercial, showing 131,000 shares and €700,885.51 on the liquidity account as of June 30, 2024. During the first half of the year, the company traded 1,515,865 shares on the buy side and 1,532,677 shares on the sell side. GENFIT’s diverse R&D portfolio includes programs targeting Acute-on-Chronic Liver Failure and other serious diseases, with a recent highlight being the FDA’s accelerated approval of their drug for Primary Biliary Cholangitis.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Revenue Surge Driven by Key Milestone
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App